Week 5 Flashcards
Capsule of lymph node
thin, fibrous (thickened/fibrotic in reactive or neoplastic conditions)
EX) Nodular sclerosis Hodgkin Lymphoma
Cortex of lymph node
contains lymphoid follicles (primary and secondary) and paracortex (interfollicular T cell zone)
Secondary follicle
mostly B cells
a. Mantle zone = small cells surrounding germinal center
- All B cells, small, uniform, tightly packed
- CD20 (also CD 19 and 22) = B cell marker (highlights mantle zone B cells and germinal center B cells)
b. Germinal center: inner side
- Dark zone = mostly B cells (centroblasts)
- Light zone = mixed B cells (centrocytes), T cells, macrophages, and other cells
- BCL6 and CD10: markers specifically expressed in normal germinal B cells and derived lymphomas
Paracortex
mixed cell populations, mostly T cells
CD3 (also CD4, 5, 8)= T cell marker - shows them abundant in paracortex and scattered in germinal center
Sinuses
subcapsular, cortical, and medullary
1.Contain lymphocytes, plasma cells, and histiocytes
Lymphoma: Immature B cells:8c
B cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (B-ALL/LBL)
Lymphoma: Mantle cell
Mantle Cell lymphoma
Lymphoma: Germinal Center B-Cell (3)
- Follicular Lymphoma
- Hodgkin Lymphoma
- Burkitt Lymphoma
Lymphoma: Pre or Post-Germinal Center B cell
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Lymphoma: Plasma cell myeloma
Plasma cell myeloma (multiple myeloma)
Lymphadenopathy and associated diseases (3)
lymph nodes of abnormal size, number or consistency
Associated diseases:
- CLL/SLL
- Follicular lymphoma - asymptomatic except for lymphadenopathy → late stage diagnosis usually
- Mantle Cell Lymphoma (MCL)
WHO classification of lymphomas (5)
Morphology, immunophenotype, genetic findings, location, and age
Clinical features of CLL and SLL
- CLL = most common leukemia (30% of all leukemias)
a. Predominantly peripheral blood lymphocytosis - SLL = 7% of Non-Hodgkin Lymphoma
a. Predominantly extramedullary involvement (nodes) - Median 65 years, male predominance (2:1 over females)
- Present asymptomatic, or mildly symptomatic
Morphology of CLL and SLL
- Mature Lymphocytosis > 5 x10^9/L sustained for at least 3 months
- Monocloncal B cell with immature phenotype
- CLL cells: small, round nuclei, clumped chromatin
- Lymph node involvement: effacement of nodal architecture with diffuse infiltration
Immunophenotype CLL and SLL
- Positive: CD5 and CD23 (t cell marker expressed by B cells - unique to this lymphoma),, CD19 (B cell)
- Weak: CD20, surface immunoglobulin, CD22, CD11c
- Negative: CD10, FMC7
Genetic alteration CLL and SLL (4)
- Deletion of 13q14
- Trisomy chr12
- Deletion 11q22-23
- Deletion 17p13
On a scale from 1-10, how much of a bitch is Charlie?
15***
*** Question adapted from USMLE Step I 2015 edition
Clinical features of follicular lymphoma (4)
- origin
- age
- Location
- stage of presentation
- Lymphoma of germinal center B cell origin
- Mostly Adults (median 60 years), male = female
- Location: lymph nodes mostly - also spleen, bone marrow, GI, skin
- Usually present with widespread stage III or IV disease at diagnosis
a. Asymptomatic except for lymphadenopathy
Morphology of follicular lymphoma
1.Neoplastic follicles, uniform in size, evenly distributed in lymph node cortex and medulla
No tingible body macrophages, no dark zone or light zone
Immunophenotype of follicular lymphoma:
Positive for?
Negative for?
Positive For:
a. B-cell markers: CD19+, CD20+
b. BCL2+ positive (normally NO BCL2 in germinal center B cells)
c. Germinal center B-cell marker: CD10 and BCL6
2.Negative: CD5, CD23
Genetic alteration for follicular lymphoma
- t(14:18) in 75-90% of cases
a. BCL2 gene (chr18) placed under influence of IGH promoter on chr14 → persistent expression in B cells → Lymphoma
Clinical features of mantle cell lymphoma (6):
- % of NHL
- median age
- M:F ratio
- Location
- Stage
- Aggressiveness
- 3-10% of NHL
- Median age = 60 years
- M:F = 2:1
- Location: mostly lymph nodes - also spleen, bone marrow, GI
- Presents as stage III or IV with lymphadenopathy, hepatosplenomegaly
a. Can have bone marrow involvement
6. Moderately aggressive (in contrast to other small B-cell lymphomas)
Morphology of mantle cell lymphoma (3)
- Effacement of lymph node architecture
- Diffuse infiltration of lymphoma cells in node
- Tumor cells: small-medium size, irregular nuclei, small nucleoli
Immunophenotype mantle cell lymphoma:
Positive for?
Negative for?
Positive for:
a.B-cell markers: CD19, CD20
b. CD5, which is also positive in CLL/SLL (typically not expressed by B cells, but MCL B cells do express CD5)
c. Cyclin D1 (BCL1), which is negative in most of other B-cell lymphomas
Negative for:
a. CD23, which is positive in CLL/SLL
b. Germinal center B-cell markers: CD10, BCL6
Genetic alteration mantle cell lymphoma
t(11:14) involving BCL1 gene on 11q13 and IGH gene on 14q32
I’m sorry Charlie, I didn’t mean to hurt your feelings
I know you are sensitive
Clinical features of Burkitt lymphoma (BL) (3)
- Highly aggressive
- Presents at extranodal sites or as leukemic form
- Mostly in children or young adults
Endemic BL
- geographic location
- age
- involvement
- % EBV positive
a. Malaria belt in Africa
b. Childhood malignancy (4-7 years of age)
c. Involves jaw or abdomen
d. 95% EBV positive
Sporadic BL
- age
- involvement
- % EBV infection
a. Mostly in children and young adults
b. Mostly in ileocecal area
c. 30% EBV infection
Immunodeficiency BL
HIV patients
a.30% EBV infection
Morphology of Burkitt lymphoma cells
Medium sized, round nuclei, one or several small nucleoli, deeply basophilic cytoplasm with vacuoles
-Diffuse infiltration of monomorphic, medium sized cells with “starry sky” pattern
Immunophenotype Burkitt lymphoma:
Positive for:
Negative for:
Positive for:
a. B cell Markers: CD19, CD20
b. Germinal Center B-cell markers: CD10, BCL6
c. High proliferation index
d. EBV positive in endemic BL (sometimes + in sporadic/immune)
e. MYC gene
Negative for: CD5, CD23, BCL2, TdT
Genetic alteration Burkitt Lymphoma
t(8;14) - juxtaposes MYC gene at 8q24 next to IGH promoter
Clinical features of diffuse large B-cell lymphoma:
- size
- % NHL cases
- age
- m:f
- where does it grow
- aggressiveness
- treat
- different types?
- Diffuse proliferation of medium to large-sized neoplastic B cells
- Most common type of non-Hodgkin’s Lymphoma (31% of cases)
- Median age = 64 years
- Slight male predominance
- Rapidly growing nodal (70% of the time) and extranodal (30% of the time) tumor
- More aggressive than other low-grade B-cell lymphomas
- Potentially curable with standard chemo (46% survival)
- Many different types of large B-cell lymphoma
Morphology of diffuse large b cell lymphoma
- Complete effacement of architecture of lymph nodes by diffuse lymphoma cell infiltrates
- Large-sized lymphoma cells, with nuclear size greater than histiocyte nucleus or small lymphocyte
Immunophenotype diffuse large B cell lymphoma
B-cell markers positive: CD19+, CD20+
Indolent (causing little to no pain) lymphomas
Small B-cell lymphomas mostly indolent (except MCL)
- CLL/SLL
- Follicular Lymphoma
Aggressive lymphomas
i. MCL = moderately aggressive
ii. Diffuse Large B-Cell Lymphoma (slightly more aggressive than other low-grade B-cell lymphomas)
Highly aggressive lymphomas
Burkitt’s Lymphoma - highly aggressive but potentially curable (60% cure)
4 common types of lymphomas in adults
i. CLL/SLL
ii. Follicular Lymphoma (FL)
iii. Mantle Cell Lymphoma (MCL)
iv. Diffuse Large B-Cell Lymphoma
Common types of lymphomas in children
Burkitt’s Lymphoma (endemic and sporadic)
BCL2 gene arrangement
Overexpression of BCL2 → massive follicular lymphoid hyperplasia, but not enough to cause neoplastic transformation
Normally no BCL2 in germinal center B cells
Follicular Lymphoma: BCL2 gene (chr18) placed under influence of IGH promoter on chr14 → persistent expression in B cells
BCL1 gene arrangement
involved in cell-cycle progression
- Cyclin D1 binds CDK4 and CDK6 → phosphorylation of Rb → release E2F1-3 transcription factors → activate genes that are required for cell cycle progression → G1/S transition → cell divides
- Mantle Cell Lymphoma:
a. Strongly/diffusely positive Cyclin D1 (BCL1) (which is negative in most of other B-cell lymphomas)
MYC gene arrangement
TF, overexpression can induce carcinogenesis of lymphoma development
Burkitt’s Lymphoma